Evommune (EVMN) Common Equity (2024 - 2026)
Evommune (EVMN) posted quarterly Common Equity of $304.6 million for Q1 2026, up 292.47% year-over-year from $77.6 million in Q1 2025, and up 48.15% quarter-over-quarter from $205.6 million in Q4 2025.
Evommune (EVMN) Common Equity (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Common Equity for 3 consecutive years, with $304.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 292.47% year-over-year to $304.6 million; the TTM figure through Mar 2026 stood at $304.6 million (up 292.47% YoY), while the FY2025 annual figure was $205.6 million, up 242.52% from the prior year.
- Common Equity advanced to $304.6 million in Q1 2026 per EVMN's latest filing, from $205.6 million in the prior quarter.
- Across five years, Common Equity topped out at $304.6 million in Q1 2026 and bottomed at -$183.1 million in Q3 2025.
- Historically, Common Equity has averaged -$16.3 million across 3 years, with a median of -$133.4 million in 2024.
- Annual changes were most pronounced in 2025 — Common Equity plunged 49.47% — and 2026, when it jumped 292.47%.
- Evommune's Common Equity stood at -$144.2 million in 2024, then surged by 242.52% to $205.6 million in 2025, then soared by 48.15% to $304.6 million in 2026.
- Business Quant data shows EVMN's Common Equity at $304.6 million in Q1 2026, $205.6 million in Q4 2025, and -$183.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 277.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 277.59 Mn |
| Mar 31, 2026 | 304.56 Mn |
| Dec 31, 2025 | 205.57 Mn |
| Sep 30, 2025 | -183.14 Mn |
| Mar 31, 2025 | -158.24 Mn |
| Dec 31, 2024 | -144.24 Mn |
| Sep 30, 2024 | -122.53 Mn |